David Pyott
Angel Investor
Orange, United States
David Pyott is a Series A investor in Orange focused on Medical and Biotechnology. David E. I. Pyott is based out of Avon, Colorado and is the Chair of London Business School and the Board of Directors of Tarsus Pharmaceuticals. David previously worked at BioMarin Pharmaceutical as a Board of Directors. David E. I. Pyott attended the University of Edinburgh. David E. I. Pyott has been awarded Harvard Business Review’s 4thbest-performing CEO in the world—2014.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries David Pyott invests in
Stages David Pyott invests in
Countries David Pyott invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $1.4M–$13M
- Series B
- $7.1M–$40M
Investment Focus
Industry
- Medical 3 (60%)
- Biotechnology 3 (60%)
- Medical Device 3 (60%)
- Health Care 2 (40%)
- Biopharma 1 (20%)
Stage
- Series A 2 (40%)
- Series B 2 (40%)
- Seed 1 (20%)
Country
- United States 3 (60%)
- The Netherlands 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular andlayered structures.Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland. | $7.1M / Series B / Aug 30, 2017 | ||
| Sienna Biopharmaceuticals (“sienna”) is a company focused on the discovery, clinical development and commercialization of products in aesthetics and dermatology based on scientific breakthroughs that dramatically improve patient outcomes and physicians’ practice of medicine. | $40M / Series B / Apr 24, 2017 | ||
| Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of concept and preclinical studies of its lead technology and seek partners to conduct clinical trials for regulatory approvaland commercialization.At Bioniz, they are committed to the discovery of novel molecules that enhance the lives of people across the globe. They perform our research with integrity and conscious, and bear in mind always our responsibility to the public health and their investors.It was founded in 2009 and headquartered in Irvine, California. | $13M / Series A / Aug 01, 2016 | ||
| Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $1.4M / Series A / Dec 03, 2015 | ||
| Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $1.4M / Seed / Dec 03, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does David Pyott invest in?
David Pyott invests primarily in Medical, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does David Pyott invest in?
David Pyott typically joins rounds of $1.4M–$13M at Series A and $7.1M–$40M at Series B. These are whole funding-round sizes, not David Pyott's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds David Pyott took part in.
How do I contact David Pyott?
Public channels for David Pyott include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did David Pyott last invest?
The most recent investment recorded for David Pyott closed in Aug 2017. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
